Summary.
NPS Pharmaceuticals, Inc. (NPS) has synthesized a series of open-channel blockers with varying potencies at the NMDA receptor. NPS 1506 (Fig. 1) is a moderate affinity antagonist that inhibits NMDA/glycine-induced increases in cytosolic calcium in cultured rat cerebellar granule cells (IC50 = 476 nM) and displaces the binding of [3H]MK-801 to rat cortical membranes (IC50 = 664 nM).
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received August 31, 1999 Accepted September 20, 1999
Rights and permissions
About this article
Cite this article
Mueller, A., Artman, L., Balandrin, M. et al. NPS 1506, a moderate affinity uncompetitive NMDA receptor antagonist: preclinical summary and clinical experience. Amino Acids 19, 177–179 (2000). https://doi.org/10.1007/s007260070047
Issue Date:
DOI: https://doi.org/10.1007/s007260070047